Technology
Multiplexed TEP(Tumor-Educated Platelet) RNA based Liquid Biopsy
Traditional liquid biopsy methods based on circulating tumor DNA (ctDNA) face limitations in detecting early-stage cancer due to low ctDNA levels.
Foretell My Health analyzes changes in platelet RNA, enabling detection earlier than ctDNA-based approaches.
Accurate early detection is critical for many cancers that currently lack effective screening methods.
Our TEP-RNA–based technology makes early detection possible and brings new cancer screening options without existing diagnostic solutions.
Foretell My Health Early Detection
Estimated 5x increase in early detection (at stage I and II)
Projected 36% improvement in survival rate
Research Results
2023. 04. AACR Poster (collaborative clinical research with SNUH)
2023. 10. Filing Patents - Korea : 10-2022-0133331- PCT : PCT/KR2023/016067
